Browse studies

Find your next paid study

90 recruiting studies matching your filters

A Phase 2 Trial of SX-682 and Pembrolizumab in Patients With Treatment Naive Stage IV or Recurrent Non-Small Cell Lung Cancer

This phase II trial tests whether CXCR1/2 inhibitor SX-682 (SX-682) with pembrolizumab works to treat patients with stage IIIC or IV non-small cell lung cancer…

Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IIIC Lung Cancer AJCC v8+1 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of WashingtonNCT05570825

Phase 2

A Front-Line Window-of-Opportunity Phase 2 Study of Tarlatamab (Bispecific T Cell Engager: DLL3-CD3) in Patients With Extensive-Stage Small-Cell Lung Cancer

This phase II trial tests the effect of tarlatamab in treating patients with small-cell lung cancer (SCLC) that has spread from where it first started to other…

Extensive Stage Lung Small Cell Carcinoma

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Asrar AlahmadiNCT07423585

Phase 2

Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)

This phase II trial tests the safety and side effects of psilocybin in combination with therapy for the treatment of major depressive disorder in patients with…

Lung Non-Small Cell CarcinomaUnipolar Depression

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Alan DavisNCT07216404

Phase 2

A Phase II Study of Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Background: Small cell carcinoma of the bladder (SCCB) and other high-grade neuroendocrine tumors (HGNET) of the urinary tract are rare but aggressive cancers…

Small Cell Carcinoma of the BladderHigh Grade Neuroendocrine Tumors of the Urinary Tract

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT06228066

Phase 2

(PRESTO) A Randomized Phase II Trial Evaluating Hotspots in Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer

This clinical trial compares stereotactic ablative radiotherapy (SBRT) with hot spots to standard of care SBRT for the treatment of patients with early-stage n…

Early Stage Lung Non-Small Cell CarcinomaStage I Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Roswell Park Cancer InstituteNCT07718672

Phase 1

A Biomarker Study of Low-Dose IL-2 Plus Pembrolizumab in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

This early phase 1 trial will investigate the combination of low-dose interleukin-2 (IL-2) and pembrolizumab in patients with previously untreated stage IV non…

Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8+1 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Emory UniversityNCT05493566